Published in Mol Cell Endocrinol on September 19, 2007
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology (2014) 2.67
Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol (2010) 1.23
Pituitary somatostatin receptor signaling. Trends Endocrinol Metab (2010) 1.03
Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology (2013) 1.03
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol (2013) 0.97
Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol (2009) 0.91
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med (2015) 0.90
Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol (2014) 0.89
Somatostatin stimulates menin gene expression by inhibiting protein kinase A. Am J Physiol Gastrointest Liver Physiol (2008) 0.89
Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary (2011) 0.88
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord (2010) 0.88
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary (2014) 0.87
A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther (2012) 0.87
Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors. Int J Clin Exp Pathol (2012) 0.84
Management of acromegaly in Latin America: expert panel recommendations. Pituitary (2010) 0.83
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary (2016) 0.83
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther (2015) 0.81
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer (2012) 0.80
Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro. Neuroendocrinology (2012) 0.79
Somatostatin and its 2A receptor in dorsal root ganglia and dorsal horn of mouse and human: expression, trafficking and possible role in pain. Mol Pain (2014) 0.79
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer Med (2016) 0.78
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer (2014) 0.78
Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's disease. Endocrinology (2008) 0.78
Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol (2013) 0.78
Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle. Open Access J Urol (2010) 0.77
Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications. J Cell Mol Med (2010) 0.77
Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept (2013) 0.77
Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. Oncologist (2016) 0.77
Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol (2016) 0.76
The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story. Curr Neuropharmacol (2013) 0.76
Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol (2016) 0.76
Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts. Oncotarget (2016) 0.75
New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol (2017) 0.75
New treatment guidelines on Cushing's disease. F1000 Med Rep (2009) 0.75
Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol (2016) 0.75
Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial. Trials (2015) 0.75
Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression. Endocrinology (2016) 0.75
The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol (2017) 0.75
Pathophysiology of Gastric NETs: Role of Gastrin and Menin. Curr Gastroenterol Rep (2017) 0.75
The effect of albumin fusion structure on the production and bioactivity of the somatostatin-28 fusion protein in Pichia pastoris. J Ind Microbiol Biotechnol (2014) 0.75
Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro. Oncotarget (2017) 0.75
Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats. Endocrine (2017) 0.75